Bioheart has entered into a joint venture with Magnum Cell Therapies.

Magnum Cell Therapies' mission is to provide the latest regenerative medicine therapies to patients suffering from degenerative diseases.

Magnum's facilities include a state of the art clinic and laboratory located in Honduras.

Bioheart will provide the necessary training and expertise to transfer Bioheart therapies to Magnum.

Bioheart and Magnum will work closely with the Honduran Ministry of Health to make Bioheart protocols part of the standard of care for patients in Honduras and neighboring countries.

Bioheart will assume 10% ownership of Magnum Cell Therapies.

Magnum will offer these therapies to the more than 8 million people living in Honduras as well as being a premier site for medical tourism.

For further deal information visit Current Agreements (subscription required)

Related

Report: Regenerative Medicine and Stem Cells Partnering Terms and Agreements

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter